Exclusion of fetal anomalies not associated with thalidomide exposure. Dependant on the severity of fetal malformation. Recent use in the U.S. market has raised concern about exposure to pregnancy. No safe dose of thalidomide treatment during the critical period has been established. Women of childbearing age who take thalidomide would be required to use two forms of birth control and take monthly pregnancy tests.
Pregnancy complicated by thalidomide exposure requires counseling for fetal malformations.
Ultrasound is the only possible tool for prenatal diagnosis of thalidomide embryopathy. Recognition of thalidomide defects. Prenatal diagnosis of thalidomide syndrome.